Compare SIMO & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIMO | MIRM |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 5.7B |
| IPO Year | 2005 | 2019 |
| Metric | SIMO | MIRM |
|---|---|---|
| Price | $277.00 | $97.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $118.13 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $42.27 | $26.22 |
| Revenue Next Year | $12.78 | $22.04 |
| P/E Ratio | $36.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $60.35 | $43.40 |
| 52 Week High | $294.00 | $114.99 |
| Indicator | SIMO | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 69.63 | 46.08 |
| Support Level | $82.55 | $95.68 |
| Resistance Level | N/A | $98.03 |
| Average True Range (ATR) | 17.86 | 5.94 |
| MACD | -0.79 | -1.04 |
| Stochastic Oscillator | 74.31 | 15.48 |
Silicon Motion Technology Corp is engaged in developing NAND flash controllers for SSDs and other solid state storage devices. Its only operating segment is to develop NAND flash controllers and SSDs solutions. The company derives revenue from product categories such as Mobile Storage, Mobile Communications, and others. Silicon's geographical segments are Taiwan, the United States, Korea, China, Singapore, Malaysia, and others. The company products are used in Personal Computing, Smartphone/Tablet/CE, Flash Card/USB Flash Drive, Industrial and Embedded, Automotive, and Enterprise and Data centers.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.